Results 71 to 80 of about 113,609 (263)

In relapsed or refractory diffuse large B‐cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine

eJHaem
CD19‐targeting treatments have shown promise in relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL). Loncastuximab tesirine (loncastuximab tesirine‐lpyl [Lonca]) is a CD19‐targeting antibody‐drug conjugate indicated for R/R DLBCL after at ...
Paolo F. Caimi, Mehdi Hamadani, Carmelo Carlo‐Stella, Masoud Nickaeen, Eric Jordie, Kiersten Utsey, Tim Knab, Francesca Zammarchi, Danilo Cucchi, Serafino Pantano, Karin Havenith, Ying Wang, Joseph Boni   +12 more
doaj   +1 more source

CD19 CAR T Cells

Cell, 2017
CARs are synthetic receptors that reprogram immune cells for therapeutic purposes. They comprise three canonical domains for antigen recognition, T cell activation, and costimulation. The CAR cDNA is genetically integrated in the T cell genome. Autologous CAR T cells are generated from the patient's peripheral blood T cells and expand in the recipient ...
openaire   +2 more sources

SOX5 Orchestrates Malignant Evolution via Promoter‐Centric Chromatin Remodeling in MYC‐Driven B‐Cell Lymphoma

Advanced Science, EarlyView.
In MYC‐enforced B‐cell lymphoma, SOX5 occupies promoter‐proximal regulatory regions and is associated with reduced chromatin accessibility at the PCNP locus. PCNP repression promotes proliferative remodeling by limiting apoptosis and cell‐cycle restraint.
Yiyou Mao, Zhenyuan Jia, Xiao‐Qin Mu, Ruilin Wang, Jianli Ma, Qingyuan Zhang, Yuwei Deng   +6 more
wiley   +1 more source

Phenotyping of P105-Negative B Cell Subsets in Patients with Systemic Lupus Erythematosus

Clinical and Developmental Immunology, 2012
This study aimed to investigate phenotype of RP105(−) B cell subsets in patients with systemic lupus erythematosus (SLE). Flow cytometry was used for phenotyping RP105-negaive B cell subsets.
Syuichi Koarada, Yoshifumi Tada, Rie Suematsu, Sachiko Soejima, Hisako Inoue, Akihide Ohta, Kohei Nagasawa   +6 more
doaj   +1 more source

Molecular Dynamics‐Guided Sterol Engineering of mRNA‐Lipid Nanoparticles Reprograms Biodistribution and Enhances Spleen‐Selective Immunity

Advanced Science, EarlyView.
Sterol engineering enables precise control of mRNA lipid nanoparticles by tuning membrane organization. Replacing cholesterol with bile acid‐derived sterols redirects protein expression from the liver to the spleen. Notably, CA‐20 LNP enhances antigen‐specific immune responses while exhibiting a favorable safety profile, highlighting sterols as a ...
Sanghyuk Jeon, Seo‐Hyeon Bae, Jungyong Ji, Jisun Lee, Hosam Choi, Min‐Ho Kang, Sang‐In Park, Hyemin Kim, Nakyung Lee, Hajin Lee, Seonghoon Kim, Jungmin Kim, Subin Yoon, Seonghyun Lee, Seongje Cho, Dahyeon Ha, Ayoung Oh, Sohee Jo, Huijeong Choi, Yeeun Lee, Sowon Lee, Hyo‐Jung Park, Gitak Nam, Jisu Shin, Yujin Kang, Wonpil Im, Kiyoun Lee, Jae‐Hwan Nam   +27 more
wiley   +1 more source

Chronic HBV Infection Disrupts CCL5‐Secreting cNK Cells and Attenuates Liver Accumulation and Activation of DCs and HBV‐Specific T Cells

Advanced Science, EarlyView.
ADORA2A activation suppresses NFκB‐dependent CCL5 production in cNK cells during chronic HBV infection, disrupting intrahepatic DC recruitment and HBV‐specific CD8+ T‐cell differentiation and function. Targeting the ADORA2A/NFκB/CCL5 axis restores antiviral immunity and facilitates HBV clearance.
Ailu Yang, Yucan Wang, Yating Yu, Jing Wu, Cuiping Bao, Zixuan Wang, Qiuju Han, Zhigang Tian, Jian Zhang, Huajun Zhao   +9 more
wiley   +1 more source

A preclinical study of allogeneic CD19 chimeric antigen receptor double‐negative T cells as an off‐the‐shelf immunotherapy drug against B‐cell malignancies

Clinical & Translational Immunology
Objectives To evaluate the manufacturability, efficacy and safety of allogeneic CD19 chimeric antigen receptor double‐negative T cells (CD19‐CAR‐DNTs) as an off‐the‐shelf therapeutic cell product.
Dan Wang, Liuyang Wang, Shuai Liu, Jianjun Tong, Honglin Zhu, Man Xu, Xiancai Li, Zhiqiang Xiang, Qinghua Sun, Hengcai Wang, Yuli Wang, Shuyang Wang, Liming Yang   +12 more
doaj   +1 more source

Immediate Growth Control in Response to Boiling Histotripsy is Prognostic for Intratumoral Immune Activation

Advanced Science, EarlyView.
Boiling Histrotripsy (BH), a mechanical form of focused ultrasound (FUS), allows for non‐invasive and non‐ionizing tissue destruction. Utilizing a BH treatment protocol that yielded bifurcating primary tumor growth responses, we found that immediate BH‐induced tumor growth control identifies tumors with acute reductions in antigen‐presenting cells (APC)
Lydia E. Kitelinger, Matthew R. DeWitt, Carly M. Van Wagoner, Claire A. Conarroe, Charles C. Funk, Aaron B. Streit, AeRyon Kim, Richard J. Price, Timothy N. J. Bullock   +8 more
wiley   +1 more source

B Cells are Activated via a Nanoporous Interface that Stabilizes Microvilli and Engages Mechanosensitive Ion Channels

Advanced Science, EarlyView.
B cells can be activated independently of antigen recognition via mechanical stimulation through nanoporous substrates. Exposure to such substrates induced B cell microvilli extension into the pores, intracellular Ca2+ signaling, phosphorylation of signaling proteins, and CD69 expression.
Nozie D. Aghaizu, Willi Weber, Nadine Strempel, Asya Polat, Enrico Klotzsch   +4 more
wiley   +1 more source

Rhoifolin Alleviates Ulcerative Colitis by Targeting NMNAT1 and Activating SIRT1‐FOXO1 Signaling to Enhance ILC3s Effector Function

Advanced Science, EarlyView.
Rhoifolin directly targets NMNAT1, thereby activating nicotinamide salvage pathway and promoting intracellular NAD+ biosynthesis. Elevated NAD+ levels enhance SIRT1 activity, leading to FOXO1 deacetylation and nuclear translocation. Nuclear FOXO1 subsequently binds to the IL‐22 promoter, upregulating IL‐22 transcription and potentiating ILC3 effector ...
Hongqiong Yang, Yishu Zhang, Sijia Feng, Xiaoqing Ma, Jiayi Feng, Junwei Wang, Jialin Gao, An Pan, Dapeng Wu, Kang Ding, Caijuan Zheng, Qi Lv, Lihong Hu   +12 more
wiley   +1 more source